Loading...
•
Sep 30, 2022
BioNano Q3 2022 Earnings Report
Reported financial results with revenue growth and progress on ELEVATE! milestones.
Key Takeaways
Bionano Genomics reported a 55% year-over-year revenue growth in Q3 2022, reaching $7.2 million, the highest quarterly revenue to date. The company is on track to achieve all 2022 ELEVATE! milestones and maintains a strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities.
Total revenue for Q3 2022 was $7.2 million, representing the highest quarterly revenue to date.
The installed base of Saphyr systems grew by 21 to 217 as of the end of Q3 2022, an 11% increase compared to Q2 2022.
Sold 3,975 nanochannel array flowcells during Q3 2022, a record for the company.
Bionano Laboratories launched, combining OGM data services with clinical testing services.
Revenue by Segment
Forward Guidance
The company expects revenues for the fourth quarter to be in the range of $7.5 million to $8 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...